Importantly, this synthetic lethality was observed in lung tumors with functional NRF2–KEAP1 signaling and overexpression of TXNRD1, indicating that the activity of the anti-oxidative response in NSCLC could be used as a biomarker for determining which patients may benefit from dual AKT/TXNRD1 inhibition (99). The gene discussed is TXNRD1; the disease is non-small cell lung carcinoma.